Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:32 AM
Ignite Modification Date: 2025-12-25 @ 10:40 PM
NCT ID: NCT05672667
Description: None
Frequency Threshold: 0
Time Frame: 1 week after intravenous oxytocin and 1 week after intranasal oxytocin.
Study: NCT05672667
Study Brief: A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Intravenous Oxytocin Infusion Study Day Oxytocin 14 micrograms infusion over 30 minutes on first study day. 0 None 0 24 4 24 View
Intranasal Oxytocin Spray Study Day Oxytocin 102 micrograms by intranasal spray on second study day. 0 None 0 24 3 24 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Rhinorrhea after intranasal oxytocin NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (10.0) View
Sternutation after intranasal oxytocin NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (10.0) View
Feeling of warmth after intravenous oxytocin NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (10.0) View
Red face after intravenous oxytocin NON_SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (10.0) View